ETUDE | PHASE | SITE |
---|---|---|
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
|
I
|
CHUV
|
INCB 123667-101: A phase I, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Histologically or citologically confirmed advanced or metastatic solid tumors
|
I
|
CHUV
|
MATAO - MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)
cancer épithélial de l'ovaire
|
III
|
CHUV, HUG
|
NAB-PIPAC: A phase IB trial of intraperitoneal cisplatin and Nab-Paclitaxel administered by pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity
Peritoneal carcinomatosis from pancreatic, oesogastric, epithelial ovarian cancers or primitive peritoneal mesothelioma
|
I
|
CHUV, HUG
|
WO42178: A Phase II, Open-label, multicenter, platform Study evaluating the efficacy and safety of Biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.
Rare ovarian tumors
|
II
|
HUG
|